issued
on 26 Nov 2024
Last Applicant/ Owned by
23 Normanby Road
Notting Hill, VIC
AU
3168
Serial Number
97427897 filed on 25th May 2022
Registration Number
N/A
Correspondent Address
Charles G. Zug
Charles G. Zug NELSON MULLINS RILEY & SCARBOROUGH LLP
SUITE 2300, IP DEPARTMENT
CHARLOTTE, NC 28202
United States
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
Scientific research, clinical research, development, advisory and consultancy services in relation to antibody production; vaccine screening, in the nature of research and development of vaccines; advisory services relating to diagnostic products for scientific research, extracellular vesical (EV) isolations, creating custom NET builds, or developing diagnostic assays; providing diagnostic testing Read More
Advisory services relating to medical diagnostic products; advisory services relating to medical diagnostic products, namely, medical diagnostic products for extracellular vesical (EV) isolations, creating custom NET builds, or developing diagnostic assays; Medical diagnostic testing services; medical diagnostic screening services in the field of diagnostic preparations
N/A
N/A
Scientific research, clinical research, development, advisory and consultancy services in relation to antibody production; vaccine screening, in the nature of research and development of vaccines; advisory services relating to diagnostic products for scientific research, extracellular vesical (EV) isolations, creating custom NET builds, or developing diagnostic assays; providing diagnostic testing services for others for scientific research purposes; scientific research for medical purposes; scientific research for medical purposes, namely, research services relating to diagnostic products for scientific research, extracellular vesical (EV) isolations, creating custom NET builds, or developing diagnostic assays; diagnostic and research services and screening in the nature of research services in the field of diagnostic preparations; preparation of reports relating to medical, scientific and technical research; provision of information relating to medical, scientific and technical research; research and development of products; research and development of products, namely, new therapeutic products in the field of gene therapeutics and cell therapeutics; research and development of products, namely, extracellular vesicle-based diagnostic products, extracellular vesicle-based therapeutic products; laboratory research in the fields of analytical chemistry, biochemistry, medicinal chemistry, drug development, biotechnology, microbiology and molecular biology; laboratory research services relating to research in the field of extracellular vesicle-based diagnostics and extracellular vesicle-based therapeutics; scientific laboratory research and analysis services; scientific laboratory research and analysis services for research and analysis of new products in the field of cell therapeutics; analysis of tissues for medical research; research and development services in the field of antibody generation; molecular target discovery and development services; recombinant human protein production cell line, namely, culturing of cells for others for scientific research purposes
N/A
N/A
Biotechnology medical apparatus for the prevention, diagnosis or treatment of cancer, neurodegenerative, inflammatory, and metabolic diseases; medical diagnostic apparatus and instruments for testing biofluids, plasma, serum, saliva, urine and cell cultures for sale in kit form; biotechnology medical apparatus, namely, medical apparatus for the capture of extracellular vesicles
N/A
N/A
Pharmaceutical, biotechnology and medical preparations and substances for the prevention, diagnosis or treatment of cancer, neurodegenerative, cardiovascular, inflammatory, and metabolic diseases; pharmaceutical, biotechnology and medical preparations and substances for the treatment, reconstruction and repair of cancer, neurodegenerative, cardiovascular, inflammatory, and metabolic diseases using antibodies or exosomes; diagnostic preparations and reagents for medical purposes; diagnostic preparations for medical laboratory use and reagents for medical purposes, namely, extracellular vesicles, RNA, protein arrays or monoclonal antibodies; monoclonal antibodies for medical purposes; monoclonal antibody fragments for medical purposes; monoclonal antibody conjugates for medical purposes; preparations for the treatment, reconstruction and repair of cancer, neurodegenerative, cardiovascular, inflammatory, and metabolic diseases using antibodies or exosomes; immunological antibodies for medical use; biological preparations for the treatment of cancer, neurodegenerative, cardiovascular, inflammatory, and metabolic diseases for medical purposes; biological preparations for the treatment of cancer, neurodegenerative, cardiovascular, inflammatory, and metabolic diseases for pharmaceutical purposes; biological substances for the treatment of cancer, neurodegenerative, cardiovascular, inflammatory, and metabolic diseases for medical use; monoclonal antibodies for diagnostic medical use; monoclonal antibodies for medical use; monoclonal antibodies for therapeutic purposes; products containing monoclonal antibodies for use in medicine; proteins for medical use in binding antibodies; proteins for medical use in detecting antibodies; reagents for use in the development of monoclonal antibodies for medical purposes; tagged antibodies for medical use; vaccines; vaccines against cancer, viral or bacterial infection; vaccines for human use; vaccine adjuvants; diagnostic preparations, reagents, pharmaceutical and biochemical anti-cancer substances, products for the prevention, diagnosis or treatment of cancer, neurodegenerative, inflammatory, and metabolic diseases, and testing materials, namely, diagnostic test strips, immunoassays, PCR or genetic tests for in-vitro diagnostic use for medical purposes; diagnostic preparations and reagents for medical purposes, namely, diagnostic biomarker reagents for medical purposes; reagents for use in diagnostic tests for medical purposes; protein arrays for use in recombinant DNA technology for medical diagnosis purposes; biological reagents for use in molecular biology for medical purposes; diagnostic preparations and reagents for medical purposes, namely, diagnostic reagents for in-vitro use for medical purposes, reagents for in-vitro laboratory use for medical purposes, reagents for use in diagnostic tests for medical purposes, diagnostic reagents for medical use for sale in kit form; reagents in kit form for conducting enzyme-linked immunosorbent assays (ELISA) for medical purposes; pharmaceutical, biotechnology and medical preparations and substances for medical use, namely, immunotherapeutic agents for the treatment of cancer; nucleic acid substances for use in genetic probe assay kits for medical use; preparations for the treatment, reconstruction and repair of antibodies, namely, biological preparations for pharmaceutical purposes
N/A
N/A
Biological reagents for scientific and research use for molecular targets for drug and vaccine development; reagents for medical research applications; reagents for medical research applications, namely, molecular targets for drug and vaccine development; biological reagents for use in molecular biology for research purposes; reagents for medical diagnosis research applications
N/A
N/A
No 97427897
No Service Mark
No
Yes
No
No
Yes
No
No
No
No
26.01.09 -
Geometric figures, objects, humans, plants or animals forming or bordering the perimeter of a circle
26.01.18 -
Three or more concentric circles
26.01.21 -
Circles that are totally or partially shaded
26.01.31 -
Five or more circles
Status Date | Action Taken |
---|---|
26th Nov 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
15th Oct 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
15th Oct 2024 | PUBLISHED FOR OPPOSITION |
25th Sep 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
12th Sep 2024 | EXAMINERS AMENDMENT -WRITTEN |
12th Sep 2024 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
12th Sep 2024 | EXAMINERS AMENDMENT E-MAILED |
12th Sep 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
12th Sep 2024 | EXAMINER'S AMENDMENT ENTERED |
09th Sep 2024 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |